Itraconazole is a triazole with a mechanism of action similar to that of ketoconazole. Endocrine side effects of ketoconazole, including impaired cortisol synthesis, have been well documented (A. Pont, J. R. Graybill, P. C. Craven, J. N. Galgiani, W. E. Dismukes, R. E. Reitz, and D. A. Stevens, Arch. Intern. Med. 144:2150Med. 144: -2153Med. 144: , 1984. We examined the adrenal response to corticotropin in 10 patients being treated with itraconazole. No impairment of cortisol synthesis could be demonstrated.
Itraconazole (R 51,211) is a broad-spectrum oral antifungal agent currently undergoing clinical trials in both dermatophyte infections and the systemic mycoses. This compound shares structural similarities with the imidazole derivative ketoconazole (5) . Furthermore, the drugs are believed to have similar mechanisms of action (19) .
Ketoconazole was first recognized to have endocrine side effects when some patients receiving the drug developed gynecomastia (3) . Further studies demonstrated interference of ketoconazole with androgen (6, 12, 14, 15) , estrogen (10, 20) , and glucocorticoid synthesis (9, 13) . Studies of steroidogenesis in cultured mouse adrenal cortex tumor cells indicate that ketoconazole directly inhibits 1-hydroxylase activity (7) . There are only a few reports in which clinically significant hypoadrenalism has been attributed to ketoconazole therapy (17, 18, 21) . The similarities between itraconazole and ketoconazole prompted us to study the adrenal response to corticotropin in patients receiving itraconazole therapy for a variety of mycotic infections.
Of 10 patients referred for therapy of documented mycotic infections, 6 had coccidioidomycosis and 1 each had mucocutaneous candidiasis, aspergilloma, cutaneous sporotrichosis, and pulmonary cryptococcosis. A brief clinical outline of the patients studied is presented in Table 1 .
Several patients had received prior antifungal therapy, and five (patients no. 1, 2, 4, 6, and 7) had been treated with ketoconazole. None of the patients received concomitant antifungal agents during itraconazole therapy.
Three additional patients (one each with aspergilloma, pulmonary coccidioidomycosis, and disseminated coccidioidomycosis) who completed baseline adrenal testing before itraconazole therapy did not consent to follow-up corticotropin studies.
The 1-h corticotropin stimulation tests were performed as previously described (1 endocrine (11) . An increasing number of reports of adverse endocrine effects of ketoconazole being used to manage certain endocrinopathies and hormone-dependent neoplasia suggests that this imidazole derivative may prove to be more useful as an endocrine drug than as an antimicrobial agent (2, 16 
